Market News (Page 124) - TendieTensor

Market News Page 124 of 158 • 3,931 articles

Sow Good to Hold Third Quarter 2025 Conference Call on Friday, November 14, 2025 at 10:00 a.m. ET

GlobeNewswire Inc. • Sow Good Inc.

Sow Good to Hold Third Quarter 2025 Conference Call on Friday, November 14, 2025 at 10:00 a.m. ET

10/31/2025 08:00 AM • Sow Good Inc. will host a conference call on November 14, 2025, at 10:00 a.m. Eastern time to discuss its third quarter financial results for the period ended September 30, 2025.

SOWG - The article is a standard conference call announcement providing routine financial communication, with no explicit positive or negative indicators about the company's performance

#conference call #financial results #Q3 2025 #freeze dried candy

Certara to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. • Certara, Inc.

Certara to Participate in Upcoming Investor Conferences

10/31/2025 08:00 AM • Certara launches AI-powered Quantitative Systems Pharmacology (QSP) platform called Certara IQ, highlighting the company's technological innovation in drug development. The company also celebrates its scientific achievements with 200 published papers and 11 scientists recognized among top cited researchers.

CERT - Company demonstrates technological innovation with new AI platform, highlights scientific achievements, and shows strong research credentials through published papers and top-cited researchers

#biosimulation #AI #drug development #QSP #pharmaceutical research

HOLDCO ASSET MANAGEMENT ISSUES PUBLIC PRESENTATION TO THE BOARD OF DIRECTORS OF EASTERN BANKSHARES, INC.

Benzinga • Prnewswire

HOLDCO ASSET MANAGEMENT ISSUES PUBLIC PRESENTATION TO THE BOARD OF DIRECTORS OF EASTERN BANKSHARES, INC.

10/31/2025 07:30 AM • HoldCo Asset Management, a Florida-based investment firm managing $2.6 billion in assets, issued a public presentation to Eastern Bankshares' Independent Board of Directors, disclosing its ownership of the company's common stock.

EBC - The presentation appears to be an informative communication about the company's stock, without explicitly positive or negative language. HoldCo owns common stock and is providing a perspective on the company's direction.

#investment #asset management #board presentation #shareholder interest

Agnico Eagle Reports Strong Q3, Forms A Critical Minerals Subsidiary

Benzinga • Stjepan Kalinic

Agnico Eagle Reports Strong Q3, Forms A Critical Minerals Subsidiary

10/31/2025 07:27 AM • Agnico Eagle Mines reported robust Q3 results with net income of $1.06 billion, strong gold production of 866,936 ounces, and created a new subsidiary called Avenir Minerals to manage critical mineral investments.

ALT - Mentioned as a key player in biodefense market without specific recent developments
AEM - Strong quarterly financial performance, record net income, robust gold production, low costs, high gold prices, and strategic creation of a new subsidiary

#gold mining #critical minerals #earnings #production #subsidiary

Amazon, Google, Beyond Meat— Investors Couldn't Stop Talking About These And More Stocks This Week

Benzinga • Rishabh Mishra

Amazon, Google, Beyond Meat— Investors Couldn't Stop Talking About These And More Stocks This Week

10/31/2025 07:22 AM • Retail investors focused on five key stocks during the week, driven by earnings reports, AI developments, and market speculation across tech, food, and internet sectors.

EBS - Listed as a key market player without specific positive or negative indicators
AMZN - Strong Q3 earnings with $180.2B revenue, 38% profit growth, AWS surge, and raised $125B AI infrastructure capex forecast

#earnings #AI #retail investors #stock market #tech stocks

The Motley Fool • Keithen Drury

Will BigBear.ai Reach $10 in 2026?

10/31/2025 07:15 AM • BigBear.ai, an AI solutions provider for government clients, faces challenges in reaching $10 per share by 2026 due to low gross margins, limited market potential, and declining revenue growth.

BVNRY - Listed as a key market player without specific positive or negative indicators
BBAI - Low gross margins (20-30% vs industry 70-90%), declining revenue, limited market scalability, and lack of profitability

#AI #government contracts #software solutions #stock analysis

Toyota, Nissan May Import US-Made Cars To Japan To Woo Trump: Report

Benzinga • Badar Shaikh

Toyota, Nissan May Import US-Made Cars To Japan To Woo Trump: Report

10/31/2025 07:09 AM • Japanese automakers Toyota and Nissan are considering importing US-made vehicles to Japan as a diplomatic gesture to reduce trade tensions with the Trump administration, despite significant technical challenges like different driving configurations.

TM - Exploring strategic diplomatic import option to manage trade relations, with potential challenges in vehicle adaptation

#trade tensions #imports #automotive #US-Japan relations #Trump administration

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

GlobeNewswire Inc. • Regeneron Pharmaceuticals

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

10/31/2025 07:00 AM • Regeneron's Dupixent was recognized as the 'Best Biotechnology Product' of 2025 by the Galien Foundation, highlighting its groundbreaking approach to treating multiple allergic and inflammatory conditions by targeting IL-4 and IL-13 signaling pathways.

GOOG - Briefly mentioned in passing without substantive discussion
REGN - Company received prestigious industry award, demonstrated scientific innovation, and highlighted successful drug development with over 1 million patients treated globally

#biotechnology #immunology #drug development #inflammation #allergic conditions

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

GlobeNewswire Inc. • Amicus Therapeutics

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

10/31/2025 07:00 AM • Amicus Therapeutics will participate in two healthcare investor conferences in November 2025, presenting at UBS Global Healthcare Conference and Jefferies Global Healthcare Conference, with live audio webcasts available.

FOLD - Company is actively engaging with investors through conference presentations, demonstrating transparency and confidence in its business strategy and potential growth

#investor conferences #healthcare #biotechnology #webcast

Upstream Bio to Participate in Upcoming November Investor Conferences

GlobeNewswire Inc. • Meggan Buckwell

Upstream Bio to Participate in Upcoming November Investor Conferences

10/31/2025 07:00 AM • Upstream Bio, a clinical-stage biotechnology company, will participate in multiple investor conferences in November 2025, presenting its research on verekitug, a potential treatment for inflammatory respiratory diseases.

UPB - Company is actively presenting at multiple investor conferences, showcasing ongoing clinical development of a novel therapeutic approach for inflammatory respiratory diseases

#biotechnology #inflammatory diseases #respiratory disorders #investor conferences #verekitug

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire Inc. • Adagene Inc.

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

10/31/2025 07:00 AM • Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

ADAG - Advancing clinical trial, positive preliminary data, FDA alignment, and potential for novel cancer therapy

#clinical trial #oncology #immunotherapy #colorectal cancer #muzastotug

Mesa Air Group enters into an Amendment to its Loan Agreement with the United States Treasury and Provides Update to its Pending Merger with Republic Airways

GlobeNewswire Inc. • Mesa Air Group, Inc.

Mesa Air Group enters into an Amendment to its Loan Agreement with the United States Treasury and Provides Update to its Pending Merger with Republic Airways

10/31/2025 07:00 AM • Mesa Air Group amended its Treasury loan agreement, extending maturity and reducing interest, while preparing for a merger with Republic Airways that would create a regional airline with estimated $1.8-2.0 billion annual revenue.

MESA - Secured loan amendment with favorable terms, progressing towards merger with strong projected financials and potential stockholder value

#merger #loan amendment #regional airline #United Airlines #capacity purchase agreement

Perspective Therapeutics to Participate in Upcoming November Conferences

GlobeNewswire Inc. • Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate in Upcoming November Conferences

10/31/2025 07:00 AM • Radiopharmaceutical company Perspective Therapeutics will participate in upcoming investor conferences, showcasing its advanced cancer treatment technology utilizing alpha-emitting isotope 212Pb for targeted radiation therapy.

CATX - Company is presenting at multiple investor conferences, highlighting ongoing clinical trials, developing innovative cancer treatment technology, and expanding its drug product candidate facilities

#radiopharmaceuticals #cancer treatment #alpha-emitting isotope #theranostic approach #clinical trials

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

GlobeNewswire Inc. • Biostem Technologies

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

10/31/2025 07:00 AM • BioStem Technologies announced successful clinical trial results for its BioRetain® allograft in treating diabetic foot ulcers, demonstrating a 53% healing probability compared to 31% with standard care.

BSEM - Reported superior clinical trial results showing significant improvement in wound healing, highlighting potential commercial and medical value of their BioRetain® technology

#diabetic foot ulcers #wound care #clinical trial #allograft #medical technology

Prediction: This Stock Will Be the Ultimate Quantum Computing Winner

The Motley Fool • Keithen Drury

Prediction: This Stock Will Be the Ultimate Quantum Computing Winner

10/31/2025 06:30 AM • Alphabet is predicted to be the ultimate quantum computing winner due to its significant technological breakthroughs, substantial financial resources, and ability to develop quantum computing technologies in-house without the existential risks faced by pure-play quantum computing companies.

GOOGL - Briefly mentioned in passing without substantive discussion
GOOG - The article highlights Alphabet's quantum computing advancements, including completing tasks 13,000 times faster than supercomputers, having substantial financial resources, and being well-positioned to develop quantum technologies without the risks of pure-play competitors

#quantum computing #technology #investment #Alphabet #Google

US-India Sign 10-Year Defense Pact For Regional Stability: 'Ties Have Never Been Stronger'

Benzinga • Namrata Sen

US-India Sign 10-Year Defense Pact For Regional Stability: 'Ties Have Never Been Stronger'

10/31/2025 06:25 AM • India and the U.S. have signed a 10-year defense framework agreement to enhance coordination, information sharing, and technology cooperation, aimed at promoting regional stability in the Indo-Pacific region.

NVDA - Briefly mentioned in passing without substantive discussion
LMT - Potential beneficiary of increased military equipment sales between U.S. and India, with discussions about potential F-35 stealth warplane sales

#defense cooperation #regional stability #Indo-Pacific #military partnership #trade

Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030

Benzinga • Neeraj Chawla

Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030

10/31/2025 06:19 AM • Kuick Research released a comprehensive study on the US Orphan Drug Market, projecting market opportunities exceeding $190 billion by 2030, with over 850 orphan drugs in clinical trials and 500 marketed orphan drugs, highlighting significant investment potential in rare disease therapeutics.

ORCL - Briefly mentioned in passing without substantive discussion
MRK - Keytruda generated nearly $29.4 billion in global revenue in 2024, demonstrating successful expansion from an orphan drug designation to a blockbuster therapeutic

#orphan drugs #rare disease #pharmaceutical investment #FDA #biotechnology

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

The Motley Fool • David Jagielski

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

10/31/2025 06:15 AM • Recursion Pharmaceuticals uses AI for drug discovery, aiming to reduce drug development time and costs. Despite ambitious claims, the company faces significant financial challenges, including substantial losses and ongoing cash burn.

RXRX - High cash losses ($649.1M), no late-stage drug trials, rising share count, declining stock price, and unproven technology make the investment risky

#AI #drug discovery #pharmaceutical #artificial intelligence #healthcare innovation

Why Smurfit Westrock Stock Was Sliding This Week

The Motley Fool • Eric Volkman

Why Smurfit Westrock Stock Was Sliding This Week

10/31/2025 06:09 AM • Smurfit Westrock reported Q3 earnings with net sales of $8 billion, a 4% year-over-year increase, but missed analyst expectations on adjusted net income, causing stock price decline.

SW - Missed analyst earnings expectations of $0.72 per share, reporting only $0.58, with CEO describing 2025 as having a 'challenging demand backdrop'. Stock price dropped over 16% week-to-date and analysts lowered price targets.

#packaging #earnings #stock performance #Q3 results

Dow Theory: A Concerning Divergence or Artifact?

Investing.com • Michael Lebowitz

Dow Theory: A Concerning Divergence or Artifact?

10/31/2025 06:07 AM • The article explores potential market warning signs through Dow Theory, highlighting divergences in transportation indices, trucking demand, and significant performance gaps between market-cap-weighted and equal-weighted S&P 500 indexes.

META - Shares fell nearly 10% despite revenue beat, with concerns about significant CapEx spending in AI and potential market worry about overinvestment

#Dow Theory #Transportation Index #Market Divergence #S&P 500 #Trucking Demand

Why Amazon’s $125 Billion AI Bet Is Different From Meta’s

Investing.com • Luis Flavio Nunes

Why Amazon’s $125 Billion AI Bet Is Different From Meta’s

10/31/2025 06:06 AM • Amazon's massive $125 billion AI infrastructure investment stands out from Meta's due to its unique ability to monetize AI infrastructure both externally through AWS and internally through retail efficiency, creating a double-layered return strategy.

SOFI - Mentioned as a comparative example for bank charter approval process, no specific performance details provided
AMZN - Demonstrates strategic AI investment with clear monetization paths through AWS and internal retail optimization, showing potential for significant returns and operational efficiency

#AI #infrastructure #cloud computing #capital expenditure #technology investment

Kuick Research Highlights Explosive Growth and M&A Momentum In Global Multispecific Antibody Market

Benzinga • Neeraj Chawla

Kuick Research Highlights Explosive Growth and M&A Momentum In Global Multispecific Antibody Market

10/31/2025 06:01 AM • Kuick Research reports the global multispecific antibodies market is experiencing rapid growth, with market potential exceeding $50 billion by 2030, driven by innovative biologics targeting multiple disease pathways across oncology, hematology, and autoimmune diseases.

CHYM - Mentioned as a competitive fintech company in the US market, no specific performance details provided
AMGN - Early entrant with successful multispecific antibody Blincyto, demonstrating first-mover advantage

#multispecific antibodies #biotechnology #market growth #M&A #pharmaceutical innovation

Hepsiburada to Announce Third Quarter 2025 Results on November 5, 2025

GlobeNewswire Inc. • Globe Newswire

Hepsiburada to Announce Third Quarter 2025 Results on November 5, 2025

10/31/2025 06:00 AM • Turkish e-commerce platform Hepsiburada will report its unaudited Q3 2025 financial results on November 5, 2025, before U.S. market opens, highlighting its hybrid e-commerce model and integrated fintech platform.

GSK - Identified as a key player in the expanding anti-inflammatory drugs market with potential for future growth
HEPS - Standard financial reporting announcement with no explicit positive or negative financial indicators, presenting routine quarterly results disclosure

#e-commerce #fintech #Turkish market #quarterly results #digital platform

Cenovus announces third-quarter 2025 results

GlobeNewswire Inc. • Cenovus Energy Inc.

Cenovus announces third-quarter 2025 results

10/31/2025 06:00 AM • Cenovus Energy reported record upstream production of 832,900 BOE/d and downstream crude throughput of 710,700 bbls/d in Q3 2025. The company generated $2.1 billion in cash from operating activities and announced an amended agreement to acquire MEG Energy, with the transaction expected to close in mid-November.

RHHBY - Recognized as a significant contributor to anti-inflammatory drug innovations and biologics development
CVE - Strong financial performance with record production volumes, increased revenues, higher operating margins, and strategic growth projects nearing completion

#oil sands #upstream production #downstream refining #MEG Energy acquisition #financial results

GlobeNewswire Inc. • Steven Lydeamore

Immuron Announces Clinical Trial Update

10/31/2025 06:00 AM • Immuron Limited submitted an Investigational New Drug (IND) application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company's Travelan® P2TD study results are delayed until November 2025 due to government shutdown, with potential implications for future dosing strategies.

PFE - Listed as a key market player with strong potential in developing advanced anti-inflammatory treatments
IMRN - Company is progressing clinical trials and regulatory submissions, with some delays but continuing active development of pharmaceutical products

#Travelan #IMM-529 #clinical trials #FDA #Clostridioides difficile #travelers' diarrhea